GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Allos Therapeutics, Inc. (ALTH) [hlAlert]

Rating:
Buy ALTH
down 70.79 %

Allos Therapeutics, Inc. (ALTH) rated Buy by ThinkEquity

Posted on: Tuesday,  Nov 24, 2009  8:25 AM ET by ThinkEquity

ThinkEquity rated Buy Allos Therapeutics, Inc. (NASDAQ: ALTH) on 11/24/2009, when the stock price was $6.30. Since
then, Allos Therapeutics, Inc. has lost 70.79% as of 09/05/2012's recent price of $1.84.
If you would have followed this ThinkEquity's recommendation on ALTH, you would have lost 70.79% of your investment in 1016 days.

Allos Therapeutics is a pharmaceutical company focused on developing andcommercializing innovative small molecule drugs, initially for improving cancer treatments. The company's lead product candidate is RSR13. RSR13 is a synthetic small molecule that increases the release of oxygen from hemoglobin, the oxygen-carrying protein contained within red blood cells.

Research is at the core of everything we do at ThinkEquity, and we're passionate about it. Employing a disciplined and rigorous process, we scrutinize the spectrum of forces at play in the growth sectors we cover. Starting with a top down analysis, we look closely at the megatrends and industry drivers that create opportunities for innovative companies. We then allocate our resources based on a long-range research roadmap that leads to deep domain expertise and a close working knowledge of the technologies, products, services and people that populate the growth sector landscape. In short, the sum result of the ThinkEquity research process is to identify and affiliate ourselves with the fastest growing private and public companies within our domain verticals.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/24/2009 8:25 AM Buy
None
6.30
as of 12/31/2009
1 Week down  -43.34 %
1 Month down  -44.04 %
3 Months down  -42.53 %
1 YTD down  -42.53 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy